Keyphrases
Activation Markers
7%
Adoptive Cell Therapy
7%
Anti-CD38
7%
Antibody Targeting
7%
Antibody-dependent Cellular Cytotoxicity
14%
Antibody-dependent Cellular Phagocytosis
7%
Antibody-mediated
7%
Antigen Presentation
7%
Antigen Processing
7%
Cancer Immune Surveillance
7%
CD38
100%
Cell-mediated
7%
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Complement-dependent Cytotoxicity
7%
CRISPR-Cas9 Technology
7%
Cytotoxic Activity
7%
Direct Cytotoxicity
7%
Ectoenzymes
7%
Fratricide
14%
Gene Manipulation
7%
Genetic Approach
14%
Genetic Engineering
7%
Hematologic
7%
Immune Response
7%
Immune System
7%
Immunotherapeutics
7%
In Vitro Activity
7%
Knock
14%
Lead Target
7%
Lysis
28%
Mediated Action
7%
Monoclonal Antibody
7%
MRNA Electroporation
7%
Multiple Myeloma
42%
Myeloma Cells
100%
Natural Killer
7%
Natural Killer Cells
100%
Near-complete
7%
Nicotinamide
100%
Plasma Cells
7%
Receptor Targets
100%
Relapsed or Refractory multiple Myeloma
7%
Self-inflicted Injury
7%
Therapeutic Monoclonal Antibody
7%
Therapeutic Potential
7%
Therapeutic Strategies
7%
Therapy Approaches
7%
Translational Research
7%
Medicine and Dentistry
Antibody Dependent Cellular Cytotoxicity
18%
Antigen Presentation
18%
Cas9
9%
Cell Line
9%
Cell Therapy
9%
Chimeric Antigen Receptor
100%
Chimeric Antigen Receptor Natural Killer Cell
18%
Clustered Regularly Interspaced Short Palindromic Repeat
9%
Complement Dependent Cytotoxicity
18%
Cytotoxicity
18%
Electroporation
9%
Immune Response
9%
Immune System
9%
Immunosurveillance
9%
In Vitro
9%
Knock Out
18%
Malignant Neoplasm
9%
Monoclonal Antibody
9%
Multiple Myeloma
100%
Multiple Myeloma Cell Line
9%
Myeloma Cell
100%
Natural Killer Cell
100%
Nicotinamide
100%
Phagocytosis
9%
Plasma Cell
9%
T Cell
9%
Target Cell
9%
Translational Research
9%
Immunology and Microbiology
Antibody-Dependent Cell-Mediated Cytotoxicity
13%
Antigen Presentation
13%
CD38
100%
Cell Line
6%
Chimeric Antigen Receptor
100%
Chimeric Antigen Receptor Natural Killer Cell
13%
Coculture
6%
Complement Dependent Cytotoxicity
13%
CRISPR/Cas9
6%
Cytotoxicity
13%
Electroporation
6%
Immune Response
6%
Immune System
6%
Immunosurveillance
6%
Monoclonal Antibody
6%
Multiple Myeloma
100%
Multiple Myeloma Cell Line
6%
Myeloma Cell
100%
Natural Killer Cell
100%
Phagocytosis
6%
Plasma Cell
6%
Surface Property
6%
T Cell
6%
Target Cell
6%
Therapeutic Antibodies
6%